Background Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK)
are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such …

Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond
to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate …

One challenging aspect in the clinical development of molecularly targeted therapies, which
represent a new and promising approach to treating cancers, has been the identification of …

Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate
metastatic tumor growth and decrease overall survival in mice receiving short-term therapy …

Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …

Background Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS
G12C , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable …

Recent progress in targeting KRAS G12C has provided both insight and inspiration for targeting
alternative KRAS mutants. In this study, we evaluated the mechanism of action and anti-…

<p id="p001">Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm
characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately …

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and
causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand…

Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …